Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Coartem® Baby in Paediatric Patients With Uncomplicated Malaria
NCT07713602Phase 4Not yet recruiting
- Sponsor
- Novartis
- Start
- Jun 2027
- Primary completion
- May 2028
01
Overview
Phase 4, open-label, single-arm trial of artemether and lumefantrine in malaria, sponsored by Novartis. Primary endpoint: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) at Day 29. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
artemetherlumefantrine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT07713602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07713602.